The Drugs Controller General of India (DCGI) has issued strict warning against any surrogate advertisements, including awareness campaigns, for presc ...

India’s drug regulator, the Central Drugs Standard Control Organisation (CDSCO), has warned pharmaceutical companies against direct or indirect promotion of prescription weight-loss medicines, ...

By Rishika Sadam March 11 (Reuters) - India's drug regulator has warned pharmaceutical companies against direct or indirect advertising of weight-loss medicines, including obesity awareness campaigns ...

The Drugs Controller General of India (DCGI) has issued strict warning against promotional activities, including “awareness campaigns," that functions as a surrogate advertisement for ...

India’s CDSCO warns pharma companies against promoting prescription weight-loss drugs like Semaglutide and Liraglutide to the public, urging ethical marketing and holistic obesity care.

The Drugs Controller General of India (DCGI) has issued strict warning against any surrogate advertisements, including awareness campaigns, for presc ...

India's drug regulator has prohibited pharmaceutical companies from advertising weight-loss medicines directly or indirectly, including through obesity awareness campaigns.

Advisory cautions companies against surrogate advertising of prescription GLP-1 therapies ...

The Centre has warned pharmaceutical companies against promoting prescription weight-loss GLP-1 drugs - popularly sold under brand names Oz.

A couple whose baby was born in Halifax via a surrogate have thanked the team at Calderdale Royal Hospital for their amazing ...

The Telangana High Court set aside a government order that denied a Hyderabad-based doctor the right to pursue surrogacy due to her complete androgen insensitivity syndrome (CAIS).

The CDSCO advisory bars direct and indirect promotion of GLP-1 weight-loss drugs, including influencer campaigns and awareness content that create brand recall among consumers ...